Jaguar Health, Inc. (NASDAQ:JAGX) Sees Significant Decrease in Short Interest

Jaguar Health, Inc. (NASDAQ:JAGX - Get Free Report) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 35,700 shares, a decline of 96.3% from the February 28th total of 953,100 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average trading volume of 22,800 shares, the short-interest ratio is currently 1.6 days.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Jaguar Health in a research report on Friday. They set a "sell" rating for the company.

Jaguar Health Stock Down 7.1 %

JAGX traded down $0.38 during trading hours on Friday, hitting $5.00. The stock had a trading volume of 17,650 shares, compared to its average volume of 27,966. Jaguar Health has a 1 year low of $4.90 and a 1 year high of $540.00. The company has a current ratio of 1.84, a quick ratio of 1.36 and a debt-to-equity ratio of 1.65. The company's fifty day simple moving average is $16.51 and its 200 day simple moving average is $23.23.

Institutional Investors Weigh In On Jaguar Health

A hedge fund recently bought a new stake in Jaguar Health stock. Virtu Financial LLC acquired a new position in shares of Jaguar Health, Inc. (NASDAQ:JAGX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,591 shares of the biotechnology company's stock, valued at approximately $35,000. Virtu Financial LLC owned approximately 0.22% of Jaguar Health as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.04% of the company's stock.

Remove Ads

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.